International immunopharmacology

Elabela APJ System may reduce bone loss in type 2 diabetes by improving blood vessel and bone growth coordination

Updated

Abstract

Elabela administration increased bone volume fraction by 10.3% and trabecular number by 1.8/mm in a mouse model of type 2 diabetes-related osteoporosis.

  • Type 2 diabetes-related osteoporosis is associated with reduced femoral H-type vessel density and decreased Elabela expression.
  • ELA administration reversed bone loss in T2DOP mice through enhanced formation of H-type vessels.
  • In vitro, ELA treatment improved the migration and tube formation of bone marrow endothelial cells under high-glucose and high-fat conditions.
  • Co-culturing ELA-treated bone marrow endothelial cells with osteoblasts increased osteogenic differentiation, as indicated by higher alkaline phosphatase activity and mineralization.
  • The protective effects of ELA were blocked by the APJ inhibitor ML221, indicating the importance of the ELA/APJ signaling pathway in this context.

Simplified

Full Text

Full text is available at the source.

Funding

Competing interests

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free